
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT
I Background Information:
A 510(k) Number
K230878
B Applicant
Ad Astra Diagnostics, Inc.
C Proprietary and Established Names
QScout Lab; QScout RLD
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 864.5220 -
GKZ Class II Automated Differential HE - Hematology
Cell Counter
II Submission/Device Overview:
A Purpose for Submission:
Clearance of a new device
B Measurand:
White blood cell count (WBC), Neutrophils (NEUT#), Lymphocytes (LYMPH#), Monocytes
(MONO#), Eosinophils (EOS#), Basophils (BASO#), Immature Granulocytes (IG#), Percent
Neutrophils (NEUT%), Percent Lymphocytes (LYMPH%), Percent Monocytes (MONO%),
Percent Eosinophils (EOS%), Percent Basophils (BASO%), Percent Immature Granulocytes
(IG%), Neutrophil to Lymphocyte Ratio (NLR)
C Type of Test:
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
GKZ			Class II	21 CFR 864.5220 -
Automated Differential
Cell Counter			HE - Hematology

--- Page 2 ---
Quantitative complete blood count (CBC) with 6-part differential: WBC, NEUT#, LYMPH#,
MONO#, EOS#, BASO#, IG#, NEUT%, LYMPH%, MONO%, EOS%, BASO%, IG%, NLR
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
B Indication(s) for Use:
The QScout Lab is a quantitative multi-parameter automated hematology analyzer intended for
in vitro diagnostic use in screening patient populations 18 years and older found in clinical
laboratories and point-of-care (POC) settings. The QScout Lab is used with the QScout RLD test
to enumerate and classify the following parameters in venous K2/K3EDTA whole blood : White
blood cell count (WBC), Neutrophils (NEUT#), Lymphocytes (LYMPH#), Monocytes
(MONO#), Eosinophils (EOS#), Basophils (BASO#), Immature Granulocytes (IG#), Percent
Neutrophils (NEUT%), Percent Lymphocytes (LYMPH%), Percent Monocytes (MONO%),
Percent Eosinophils (EOS%), Percent Basophils (BASO%), Percent Immature Granulocytes
(IG%), Neutrophil to Lymphocyte Ratio (NLR)
C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
D Special Instrument Requirements:
QScout Lab
IV Device/System Characteristics:
A Device Description:
The QScout system is intended for in vitro diagnostic use in screening patient populations found
in clinical laboratories and point-of-care (POC) settings. The QScout system is a quantitative
multi-parameter automated hematology analyzer that provides results for complete blood count
(CBC) parameters with a 6-part differential. It includes the QScout Lab analyzer, the QScout
RLD (Rapid Leukocyte Differential) test, software, and handheld barcode scanner. The QScout
Lab is a tabletop automated hematology analyzer operated through a touch screen interface. The
QScout RLD test package contains the reagents to run the test and the port to which the blood
sample is dispensed. The system is supplied with a Barcode Scanner and stand for the scanner.
The QScout system reports white blood cell count and neutrophil to lymphocyte ratio and
enumerates and classifies six white blood cell types including neutrophils, lymphocytes,
monocytes, eosinophils, basophils, and immature granulocytes.
B Principle of Operation:
The QScout RLD test includes a microfluidic chamber of predetermined volume containing a
dried reagent of organic compounds to stain and fluoresce white blood cells. Venous whole
K230878 - Page 2 of 14

--- Page 3 ---
blood is transferred manually using a pipette capable of transferring 10Î¼L to the QScout RLD
test where cells mix with the reagent. The QScout RLD test is inserted into the QScout Lab, a
quantitative multi-parameter automated hematology analyzer, where an optical imaging system
takes images of the test chamber. A fixed (locked) machine vision algorithm identifies cells from
the images in real time. When analysis is complete, the results are displayed on the screen and
can be printed.
C Instrument Description Information:
1. Instrument Name:
QScout Lab
2. Specimen Identification:
Specimen identification is performed by manual keyboard entry or use of a barcode reader.
3. Specimen Sampling and Handling:
The QScout system can be used with venous anticoagulated whole blood samples collected
in K EDTA or K EDTA tubes. Venous whole blood samples are collected into K EDTA or
2 3 2
K EDTA tubes using each user facilityâ€™s standard procedure. Venous whole blood should be
3
sufficiently mixed and stored at room temperature for less than three (3) hours before use.
Venous whole blood is transferred manually using a pipette capable of transferring 10 Î¼L.
4. Calibration:
The QScout Lab device is factory calibrated prior to shipping to the end user, and no further
calibration is needed.
5. Quality Control:
QScout BCS Control is a three-level biological quality control solution which is available to
monitor system performance over time. This includes low, normal, and high levels prepared
from bovine and porcine leukocytes with human erythrocytes suspended in a plasma-like
solution. The biological controls are run every seven (7) days.
A two-level synthetic bead control solution is available to monitor counting capability and
optical system performance metrics of the QScout Lab analyzer. The synthetic controls
should be run weekly.
Both quality control types are produced by AAD, who can be contacted to order
replacements.
V Substantial Equivalence Information:
K230878 - Page 3 of 14

--- Page 4 ---
A Predicate Device Name(s):
Beckman Coulter UniCel DxH 800 Coulter Cellular Analysis System
B Predicate 510(k) Number(s):
K140911
C Comparison with Predicate(s):
Device & Predicate
K230878 K140911
Device(s):
Beckman Coulter
QScout Lab, QScout UniCel DxH 800
Device Trade Name
RLD Coulter Cellular
Analysis System
General Device
Characteristic Similarities
The QScout Lab is a The UniCel DxH 800
quantitative multi- Analyzer is a
parameter automated quantitative multi-
hematology analyzer parameter, automated
intended for in vitro hematology analyzer for
diagnostic use in in vitro diagnostic use
screening patient in screening patient
populations found in populations found in
clinical laboratories and clinical laboratories.
point-of-care (POC) The UniCel DxH 800
settings. The QScout Analyzer identifies and
Lab is used with the enumerates the
QScout RLD test to parameters indicated
enumerate and classify below on the following
the following sample types:
Intended Use/Indications parameters in venous
â€¢ Whole Blood (Venous
For Use K2/K3EDTA whole
and Capillary) â€“ WBC,
blood:
RBC, HGB, HCT,
â€¢ White blood cell count MCV, MCH, MCHC,
(WBC) RDW, RDW-SD, PLT,
â€¢ Neutrophils (NEUT#) MPV, NE%, NE#,
LY%, LY#, MO%,
â€¢ Lymphocytes
MO#, EO%, EO#,
(LYMPH#)
BA%, BA#, NRBC%,
â€¢ Monocytes (MONO#)
NRBC#, RET%, RET#,
â€¢ Eosinophils (EOS#)
MRV, IRF
â€¢ Basophils (BASO#)
â€¢ Pre-Diluted Whole
â€¢ Immature Blood (Venous and
Granulocytes (IG#)
Capillary) â€“ WBC,
â€¢ Percent Neutrophils RBC, HGB, HCT,
(NEUT%) MCV, MCH, MCHC,
K230878 - Page 4 of 14

[Table 1 on page 4]
	Device & Predicate		K230878	K140911
	Device(s):			
Device Trade Name			QScout Lab, QScout
RLD	Beckman Coulter
UniCel DxH 800
Coulter Cellular
Analysis System
	General Device			
	Characteristic Similarities			
Intended Use/Indications
For Use			The QScout Lab is a
quantitative multi-
parameter automated
hematology analyzer
intended for in vitro
diagnostic use in
screening patient
populations found in
clinical laboratories and
point-of-care (POC)
settings. The QScout
Lab is used with the
QScout RLD test to
enumerate and classify
the following
parameters in venous
K2/K3EDTA whole
blood:
â€¢ White blood cell count
(WBC)
â€¢ Neutrophils (NEUT#)
â€¢ Lymphocytes
(LYMPH#)
â€¢ Monocytes (MONO#)
â€¢ Eosinophils (EOS#)
â€¢ Basophils (BASO#)
â€¢ Immature
Granulocytes (IG#)
â€¢ Percent Neutrophils
(NEUT%)	The UniCel DxH 800
Analyzer is a
quantitative multi-
parameter, automated
hematology analyzer for
in vitro diagnostic use
in screening patient
populations found in
clinical laboratories.
The UniCel DxH 800
Analyzer identifies and
enumerates the
parameters indicated
below on the following
sample types:
â€¢ Whole Blood (Venous
and Capillary) â€“ WBC,
RBC, HGB, HCT,
MCV, MCH, MCHC,
RDW, RDW-SD, PLT,
MPV, NE%, NE#,
LY%, LY#, MO%,
MO#, EO%, EO#,
BA%, BA#, NRBC%,
NRBC#, RET%, RET#,
MRV, IRF
â€¢ Pre-Diluted Whole
Blood (Venous and
Capillary) â€“ WBC,
RBC, HGB, HCT,
MCV, MCH, MCHC,

--- Page 5 ---
â€¢ Percent Lymphocytes RDW, RDW-SD,
(LYMPH%) PLT, MPV
â€¢ Percent Monocytes â€¢ Body Fluids
(MONO%) (cerebrospinal, serous
â€¢ Percent Eosinophils and synovial) â€“ TNC
(EOS%) and RBC
â€¢ Percent Basophils
(BASO%)
â€¢ Percent Immature
Granulocytes (IG%)
â€¢ Neutrophil to
Lymphocyte Ratio
(NLR)
Regulation 21 CFR 864.5220 Same
Product code / class GKZ Same
Target population (age) Adults only (18 and up) Pediatric and Adults
Capillary and venous
whole blood; diluted
Venous whole blood
Specimen type whole blood; body
(K2, K3 EDTA)
fluids (CSF, serous,
synovial)
3 Level Biological 3 Level Whole Blood
Controls Control
Quality Control
2 Level Synthetic Electrical processing/
Controls flow rate Control
General Device
Characteristic Differences
Intended Use sites Clinical and POC Clinical lab only
1. Coulter principle of
automated cell counting
and sizing.
White blood cells are
stained within a 2. Photometric
microfluidic chamber measurement of HgB.
and scanned with an 3. VCSn technology for
optical imaging system. WBC differential,
Test Principle Each image is analyzed NRBC, and RET. Cells
are mixed with reagent
by a machine vision
and the prepared sample
algorithm to count and
is delivered to a flow
differentiate the white
cell where light scatter,
blood cells.
cell volume, and cell
conductivity are
measured.
Throughput 25 samples/hour >72 samples/hour
K230878 - Page 5 of 14

[Table 1 on page 5]
			â€¢ Percent Lymphocytes
(LYMPH%)
â€¢ Percent Monocytes
(MONO%)
â€¢ Percent Eosinophils
(EOS%)
â€¢ Percent Basophils
(BASO%)
â€¢ Percent Immature
Granulocytes (IG%)
â€¢ Neutrophil to
Lymphocyte Ratio
(NLR)	RDW, RDW-SD,
PLT, MPV
â€¢ Body Fluids
(cerebrospinal, serous
and synovial) â€“ TNC
and RBC
Regulation			21 CFR 864.5220	Same
Product code / class			GKZ	Same
Target population (age)			Adults only (18 and up)	Pediatric and Adults
Specimen type			Venous whole blood
(K2, K3 EDTA)	Capillary and venous
whole blood; diluted
whole blood; body
fluids (CSF, serous,
synovial)
Quality Control			3 Level Biological
Controls
2 Level Synthetic
Controls	3 Level Whole Blood
Control
Electrical processing/
flow rate Control
	General Device			
	Characteristic Differences			
Intended Use sites			Clinical and POC	Clinical lab only
Test Principle			White blood cells are
stained within a
microfluidic chamber
and scanned with an
optical imaging system.
Each image is analyzed
by a machine vision
algorithm to count and
differentiate the white
blood cells.	1. Coulter principle of
automated cell counting
and sizing.
2. Photometric
measurement of HgB.
3. VCSn technology for
WBC differential,
NRBC, and RET. Cells
are mixed with reagent
and the prepared sample
is delivered to a flow
cell where light scatter,
cell volume, and cell
conductivity are
measured.
Throughput			25 samples/hour	>72 samples/hour

--- Page 6 ---
165Î¼L (automated;
Sample Volume 10Î¼L (manual)
aspiration volume)
As needed by the
Calibration Factory Calibrated
operator
VI Standards/Guidance Documents Referenced:
â€¢ IEC 60601-1-2:2007, Medical Electrical Equipment Part 1-2: General Requirements for
Basic Safety and Essential Performance Collateral Standard: Electromagnetic Compatibility
â€¢ CLSI H20-A2 (2007): Reference Leukocyte (WBC) Differential Count (Proportional) and
â€¢ Evaluation of Instrumental Methods; Approved Standardâ€”Second Edition
â€¢ CLSI H26-A2 (2010): Validation, Verification, and Quality Assurance of Automated
Hematology Analyzers; Approved Standardâ€”Second Edition
â€¢ CLSI EP17-A2 (2012): Evaluation of Detection Capability for Clinical Laboratory
Measurement Procedures; Approved Guideline â€“ Second Edition
â€¢ CLSI EP07 (2018): Interference Testing in Clinical Chemistry; Approved Guideline â€“ Third
Edition
â€¢ CLSI EP09-c (2018): Measurement Procedure Comparison and Bias Estimation Using
Patient Samples; Approved Guideline â€“ Third Edition
â€¢ CLSI EP05-A3 (2014): Evaluation of Precision of Quantitative Measurement Procedures;
Approved Guideline â€“ Third Edition
â€¢ CLSI EP06-A2 (2020): Evaluation of the Linearity of Quantitative Measurement Procedures;
Approved Guideline â€“ Second Edition
â€¢ CLSI EP28-A3c (2010): Defining, Establishing, and Verifying Reference Intervals in the
Clinical Laboratory; Approved Guidelineâ€”Third Edition
â€¢ CLSI EP25-A (2009): Evaluation of Stability of In Vitro Diagnostic Reagents; Approved
â€¢ Guideline â€“ First Edition
â€¢ CLSI EP37 (2018): Supplemental Tables for Interference Testing in Clinical Chemistry;
Approved guideline â€“ First Edition
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision:
a) Repeatability: The study was conducted at two (2) POC sites with six (6) operators using
31 K3EDTA or K2EDTA venous whole blood samples over 19 days with four (4)
QScout Lab analyzers. Samples were tested 20 times for all parameters. Results were
obtained within 3 hours of sample collection. For each reported parameter and for each
sample tested, the mean, SD, and %CV were calculated along with the 95% CI of the SD
and %CV. The study met the pre-defined acceptance criteria for all parameters.
Parameter WBC Range N Samples N Replicates Mean Pooled SD Pooled CV%
K230878 - Page 6 of 14

[Table 1 on page 6]
Sample Volume	10Î¼L (manual)	165Î¼L (automated;
aspiration volume)
Calibration	Factory Calibrated	As needed by the
operator

[Table 2 on page 6]
Parameter	WBC Range	N Samples	N Replicates	Mean	Pooled SD	Pooled CV%

--- Page 7 ---
WBC WBC<4 x103 /ÂµL 12 21 - 31 1.55 0.08 6.07
x103 /ÂµL WBCâ‰¥4 x103 /ÂµL 19 20 - 31 10.84 0.42 3.64
NEUT# WBC<4 x103 /ÂµL 12 21 - 31 0.79 0.05 15.05
x103 /ÂµL WBCâ‰¥4 x103 /ÂµL 19 20 - 31 7.36 0.33 4.22
LYMPH# WBC<4 x103 /ÂµL 12 21 - 31 0.54 0.05 11.45
x103 /ÂµL WBCâ‰¥4 x103 /ÂµL 19 20 - 31 2.06 0.13 6.01
MONO# WBC<4 x103 /ÂµL 12 21 - 31 0.17 0.02 25.17
x103 /ÂµL WBCâ‰¥4 x103 /ÂµL 19 20 - 31 0.93 0.08 9.87
EOS# WBC<4 x103 /ÂµL 12 21 - 31 0.03 0.01 N/A
x103 /ÂµL WBCâ‰¥4 x103 /ÂµL 19 20 - 31 0.11 0.02 28.14
BASO# WBC<4 x103 /ÂµL 12 21 - 31 0.01 0.01 N/A
x103 /ÂµL WBCâ‰¥4 x103 /ÂµL 19 20 - 31 0.03 0.01 N/A
IG# WBC<4 x103 /ÂµL 12 21 - 31 0.02 0.01 N/A
x103 /ÂµL WBCâ‰¥4 x103 /ÂµL 19 20 - 31 0.34 0.07 33.42
WBC<4 x103 /ÂµL 12 21 - 31 42.89 2.31 13.21
NEUT%
WBCâ‰¥4 x103 /ÂµL 19 20 - 31 65.13 1.31 2.34
WBC<4 x103 /ÂµL 12 21 - 31 41.69 2.37 8.84
LYMPH%
WBCâ‰¥4 x103 /ÂµL 19 20 - 31 21.78 0.80 5.22
WBC<4 x103 /ÂµL 12 21 - 31 11.90 1.94 23.54
MONO%
WBCâ‰¥4 x103 /ÂµL 19 20 - 31 8.87 0.81 8.82
WBC<4 x103 /ÂµL 12 21 - 31 1.69 0.54 80.58
EOS%
WBCâ‰¥4 x103 /ÂµL 19 20 - 31 1.09 0.24 28.26
WBC<4 x103 /ÂµL 12 21 - 31 0.66 0.45 93.77
BASO%
WBCâ‰¥4 x103 /ÂµL 19 20 - 31 0.42 0.12 N/A
WBC<4 x103 /ÂµL 12 21 - 31 1.17 0.69 67.87
IG%
WBCâ‰¥4 x103 /ÂµL 19 20 - 31 2.70 0.59 31.95
WBC<4 x103 /ÂµL 12 21 - 31 2.49 0.56 18.48
NLR
WBCâ‰¥4 x103 /ÂµL 19 20 - 31 6.15 0.62 6.21
b) Reproducibility: The study was conducted at three (3) sites (2 POC and 1 clinical lab),
over five (5) days with two (2) runs per day and three (3) replicates per run using QScout
BCS Hematology Control (a 3-level control set) comprising low, normal and high levels
of measurands. Throughout the study, three (3) QScout Lab analyzers and six (6) lots of
the QScout RLD test cartridges were utilized by a total of eight (8) operators. The data
was used to calculate between-day, between-run, between-site (includes variability of
different systems and operators), and reproducibility (total precision), using a nested
ANOVA model for statistical analysis. For each reported parameter and for each level of
control tested, the mean, SD and %CV were calculated. All components of calculated
variation met the pre-defined acceptance criteria.
K230878 - Page 7 of 14

[Table 1 on page 7]
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	10.84	0.42	3.64
NEUT#
x103 /ÂµL	WBC<4 x103 /ÂµL	12	21 - 31	0.79	0.05	15.05
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	7.36	0.33	4.22
LYMPH#
x103 /ÂµL	WBC<4 x103 /ÂµL	12	21 - 31	0.54	0.05	11.45
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	2.06	0.13	6.01
MONO#
x103 /ÂµL	WBC<4 x103 /ÂµL	12	21 - 31	0.17	0.02	25.17
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	0.93	0.08	9.87
EOS#
x103 /ÂµL	WBC<4 x103 /ÂµL	12	21 - 31	0.03	0.01	N/A
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	0.11	0.02	28.14
BASO#
x103 /ÂµL	WBC<4 x103 /ÂµL	12	21 - 31	0.01	0.01	N/A
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	0.03	0.01	N/A
IG#
x103 /ÂµL	WBC<4 x103 /ÂµL	12	21 - 31	0.02	0.01	N/A
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	0.34	0.07	33.42
NEUT%	WBC<4 x103 /ÂµL	12	21 - 31	42.89	2.31	13.21
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	65.13	1.31	2.34
LYMPH%	WBC<4 x103 /ÂµL	12	21 - 31	41.69	2.37	8.84
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	21.78	0.80	5.22
MONO%	WBC<4 x103 /ÂµL	12	21 - 31	11.90	1.94	23.54
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	8.87	0.81	8.82
EOS%	WBC<4 x103 /ÂµL	12	21 - 31	1.69	0.54	80.58
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	1.09	0.24	28.26
BASO%	WBC<4 x103 /ÂµL	12	21 - 31	0.66	0.45	93.77
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	0.42	0.12	N/A
IG%	WBC<4 x103 /ÂµL	12	21 - 31	1.17	0.69	67.87
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	2.70	0.59	31.95
NLR	WBC<4 x103 /ÂµL	12	21 - 31	2.49	0.56	18.48
	WBCâ‰¥4 x103 /ÂµL	19	20 - 31	6.15	0.62	6.21

--- Page 8 ---
Within Run Between Run Between Day Between Lot Between Site Reproducibility
Parameter Control Mean N SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
x103/Î¼L or Level Value
%
Low 3.17 180 0.15 4.69 0.04 1.20 0.00 0.00 0.04 1.23 0.08 2.59 0.18 5.54
WBC Normal 8.02 180 0.28 3.48 0.26 3.24 0.08 0.95 0.00 0.00 0.14 1.68 0.41 5.10
High 20.90 180 0.78 3.71 0.40 1.92 0.00 0.00 0.23 1.08 0.23 1.10 0.93 4.45
Low 1.52 180 0.09 6.20 0.00 0.00 0.00 0.00 0.03 1.84 0.02 1.12 0.10 6.45
NEUT# Normal 4.64 180 0.19 3.99 0.14 2.95 0.04 0.86 0.00 0.00 0.07 1.44 0.24 5.23
High 13.22 180 0.59 4.46 0.22 1.63 0.04 0.30 0.15 1.15 0.12 0.87 0.66 4.98
Low 1.09 180 0.08 6.88 0.04 3.21 0.02 1.83 0.00 0.00 0.04 3.85 0.10 8.66
LYMPH# Normal 1.89 180 0.11 5.68 0.09 4.87 0.03 1.75 0.00 0.00 0.08 4.18 0.17 8.62
High 3.17 180 0.17 5.44 0.13 4.10 0.04 1.36 0.00 0.00 0.09 2.87 0.24 7.44
Low 0.35 180 0.04 12.68 0.01 3.14 0.00 0.57 0.01 2.29 0.03 8.57 0.06 15.79
MONO# Normal 0.59 180 0.05 8.53 0.02 2.54 0.01 2.03 0.02 3.90 0.03 4.41 0.06 10.80
High 1.10 180 0.09 7.88 0.04 4.00 0.00 0.00 0.00 0.00 0.08 7.00 0.12 10.91
Low 0.14 180 0.02 16.17 0.01 7.14 0.00 0.00 0.00 0.00 0.00 0.00 0.03 18.27
EOS# Normal 0.67 180 0.08 11.45 0.00 0.00 0.00 0.00 0.02 2.39 0.02 2.39 0.08 11.86
High 2.62 180 0.25 9.70 0.03 1.07 0.00 0.00 0.06 2.14 0.03 0.95 0.26 9.91
Low 0.03 180 0.01 39.89 0.00 10.00 0.00 3.33 0.00 0.00 0.00 6.67 0.01 42.28
BASO# Normal 0.14 180 0.03 22.82 0.01 9.29 0.00 0.00 0.01 9.29 0.02 10.71 0.04 27.80
High 0.52 180 0.08 14.47 0.00 0.00 0.00 0.00 0.03 4.81 0.02 4.04 0.08 15.60
Low 0.04 180 0.01 31.63 0.00 0.00 0.00 0.00 0.00 10.00 0.00 10.00 0.01 35.26
IG# Normal 0.10 180 0.03 27.14 0.01 13.00 0.00 0.00 0.00 0.00 0.02 20.00 0.04 35.82
High 0.27 180 0.06 20.71 0.02 8.89 0.00 0.00 0.02 7.04 0.06 20.37 0.09 30.89
Low 48.06 180 1.74 3.62 0.78 1.62 0.47 0.97 0.00 0.00 0.78 1.61 2.11 4.36
NEUT% Normal 57.81 180 1.35 2.34 0.23 0.40 0.32 0.55 0.00 0.00 0.25 0.44 1.43 2.44
High 63.25 180 1.45 2.29 0.14 0.22 0.40 0.63 0.00 0.00 0.00 0.00 1.51 2.40
Low 34.49 180 1.65 4.79 0.57 1.66 0.59 1.71 0.00 0.00 0.46 1.34 1.90 5.48
LYMPH% Normal 23.51 180 1.01 4.31 0.58 2.45 0.27 1.14 0.00 0.00 0.57 2.43 1.33 5.54
High 15.18 180 0.67 4.44 0.44 2.87 0.24 1.56 0.00 0.00 0.28 1.83 0.88 5.65
Low 10.96 180 1.39 12.70 0.00 0.00 0.08 0.68 0.25 2.32 0.65 5.90 1.56 14.21
MONO% Normal 7.39 180 0.62 8.35 0.20 2.65 0.11 1.46 0.20 2.68 0.22 3.02 0.72 9.75
High 5.24 180 0.42 8.08 0.15 2.90 0.11 2.12 0.00 0.00 0.31 5.84 0.56 10.42
Low 4.47 180 0.69 15.43 0.23 5.08 0.00 0.00 0.00 0.00 0.12 2.60 0.74 16.62
EOS% Normal 8.31 180 0.86 10.31 0.00 0.00 0.00 0.00 0.24 2.83 0.35 4.20 0.95 11.40
High 12.53 180 1.08 8.65 0.00 0.00 0.14 1.13 0.20 1.60 0.14 1.11 1.12 9.06
Low 0.87 180 0.33 37.51 0.11 12.76 0.04 4.37 0.00 0.00 0.10 10.80 0.36 41.29
BASO% Normal 1.70 180 0.37 21.72 0.15 8.53 0.00 0.00 0.16 9.24 0.22 12.88 0.48 27.22
High 2.48 180 0.35 14.04 0.03 1.37 0.00 0.00 0.10 4.15 0.13 5.36 0.39 15.67
Low 1.15 180 0.37 32.00 0.00 0.00 0.02 1.91 0.13 10.87 0.13 11.48 0.41 35.76
IG% Normal 1.28 180 0.34 26.18 0.13 10.08 0.00 0.00 0.00 0.00 0.25 19.53 0.44 34.21
High 1.31 180 0.27 20.82 0.11 8.63 0.03 2.52 0.08 6.11 0.28 21.53 0.42 32.02
Low 1.40 180 0.11 7.48 0.05 3.57 0.04 2.86 0.00 0.00 0.04 3.07 0.13 9.10
NLR Normal 2.47 180 0.14 5.72 0.09 3.48 0.05 1.82 0.00 0.00 0.07 2.87 0.19 7.32
High 4.18 180 0.20 4.85 0.14 3.37 0.09 2.03 0.00 0.00 0.09 2.13 0.28 6.36
2. Linearity: Linearity was determined for WBC using venous K2EDTA whole blood. A
linearity panel of 10 concentrations were tested between 8 to 14 times. The weighted least
squares (WLS) analysis was used to assess linearity. Linearity was established between a
range of 0.5 to 60 x103/Î¼L for WBC.
K230878 - Page 8 of 14

[Table 1 on page 8]
				Within Run		Between Run		Between Day		Between Lot		Between Site		Reproducibility	
Parameter
x103/Î¼L or
%	Control
Level	Mean
Value	N	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV
WBC	Low	3.17	180	0.15	4.69	0.04	1.20	0.00	0.00	0.04	1.23	0.08	2.59	0.18	5.54
	Normal	8.02	180	0.28	3.48	0.26	3.24	0.08	0.95	0.00	0.00	0.14	1.68	0.41	5.10
	High	20.90	180	0.78	3.71	0.40	1.92	0.00	0.00	0.23	1.08	0.23	1.10	0.93	4.45
NEUT#	Low	1.52	180	0.09	6.20	0.00	0.00	0.00	0.00	0.03	1.84	0.02	1.12	0.10	6.45
	Normal	4.64	180	0.19	3.99	0.14	2.95	0.04	0.86	0.00	0.00	0.07	1.44	0.24	5.23
	High	13.22	180	0.59	4.46	0.22	1.63	0.04	0.30	0.15	1.15	0.12	0.87	0.66	4.98
LYMPH#	Low	1.09	180	0.08	6.88	0.04	3.21	0.02	1.83	0.00	0.00	0.04	3.85	0.10	8.66
	Normal	1.89	180	0.11	5.68	0.09	4.87	0.03	1.75	0.00	0.00	0.08	4.18	0.17	8.62
	High	3.17	180	0.17	5.44	0.13	4.10	0.04	1.36	0.00	0.00	0.09	2.87	0.24	7.44
MONO#	Low	0.35	180	0.04	12.68	0.01	3.14	0.00	0.57	0.01	2.29	0.03	8.57	0.06	15.79
	Normal	0.59	180	0.05	8.53	0.02	2.54	0.01	2.03	0.02	3.90	0.03	4.41	0.06	10.80
	High	1.10	180	0.09	7.88	0.04	4.00	0.00	0.00	0.00	0.00	0.08	7.00	0.12	10.91
EOS#	Low	0.14	180	0.02	16.17	0.01	7.14	0.00	0.00	0.00	0.00	0.00	0.00	0.03	18.27
	Normal	0.67	180	0.08	11.45	0.00	0.00	0.00	0.00	0.02	2.39	0.02	2.39	0.08	11.86
	High	2.62	180	0.25	9.70	0.03	1.07	0.00	0.00	0.06	2.14	0.03	0.95	0.26	9.91
BASO#	Low	0.03	180	0.01	39.89	0.00	10.00	0.00	3.33	0.00	0.00	0.00	6.67	0.01	42.28
	Normal	0.14	180	0.03	22.82	0.01	9.29	0.00	0.00	0.01	9.29	0.02	10.71	0.04	27.80
	High	0.52	180	0.08	14.47	0.00	0.00	0.00	0.00	0.03	4.81	0.02	4.04	0.08	15.60
IG#	Low	0.04	180	0.01	31.63	0.00	0.00	0.00	0.00	0.00	10.00	0.00	10.00	0.01	35.26
	Normal	0.10	180	0.03	27.14	0.01	13.00	0.00	0.00	0.00	0.00	0.02	20.00	0.04	35.82
	High	0.27	180	0.06	20.71	0.02	8.89	0.00	0.00	0.02	7.04	0.06	20.37	0.09	30.89
NEUT%	Low	48.06	180	1.74	3.62	0.78	1.62	0.47	0.97	0.00	0.00	0.78	1.61	2.11	4.36
	Normal	57.81	180	1.35	2.34	0.23	0.40	0.32	0.55	0.00	0.00	0.25	0.44	1.43	2.44
	High	63.25	180	1.45	2.29	0.14	0.22	0.40	0.63	0.00	0.00	0.00	0.00	1.51	2.40
LYMPH%	Low	34.49	180	1.65	4.79	0.57	1.66	0.59	1.71	0.00	0.00	0.46	1.34	1.90	5.48
	Normal	23.51	180	1.01	4.31	0.58	2.45	0.27	1.14	0.00	0.00	0.57	2.43	1.33	5.54
	High	15.18	180	0.67	4.44	0.44	2.87	0.24	1.56	0.00	0.00	0.28	1.83	0.88	5.65
MONO%	Low	10.96	180	1.39	12.70	0.00	0.00	0.08	0.68	0.25	2.32	0.65	5.90	1.56	14.21
	Normal	7.39	180	0.62	8.35	0.20	2.65	0.11	1.46	0.20	2.68	0.22	3.02	0.72	9.75
	High	5.24	180	0.42	8.08	0.15	2.90	0.11	2.12	0.00	0.00	0.31	5.84	0.56	10.42
EOS%	Low	4.47	180	0.69	15.43	0.23	5.08	0.00	0.00	0.00	0.00	0.12	2.60	0.74	16.62
	Normal	8.31	180	0.86	10.31	0.00	0.00	0.00	0.00	0.24	2.83	0.35	4.20	0.95	11.40
	High	12.53	180	1.08	8.65	0.00	0.00	0.14	1.13	0.20	1.60	0.14	1.11	1.12	9.06
BASO%	Low	0.87	180	0.33	37.51	0.11	12.76	0.04	4.37	0.00	0.00	0.10	10.80	0.36	41.29
	Normal	1.70	180	0.37	21.72	0.15	8.53	0.00	0.00	0.16	9.24	0.22	12.88	0.48	27.22
	High	2.48	180	0.35	14.04	0.03	1.37	0.00	0.00	0.10	4.15	0.13	5.36	0.39	15.67
IG%	Low	1.15	180	0.37	32.00	0.00	0.00	0.02	1.91	0.13	10.87	0.13	11.48	0.41	35.76
	Normal	1.28	180	0.34	26.18	0.13	10.08	0.00	0.00	0.00	0.00	0.25	19.53	0.44	34.21
	High	1.31	180	0.27	20.82	0.11	8.63	0.03	2.52	0.08	6.11	0.28	21.53	0.42	32.02
NLR	Low	1.40	180	0.11	7.48	0.05	3.57	0.04	2.86	0.00	0.00	0.04	3.07	0.13	9.10
	Normal	2.47	180	0.14	5.72	0.09	3.48	0.05	1.82	0.00	0.00	0.07	2.87	0.19	7.32
	High	4.18	180	0.20	4.85	0.14	3.37	0.09	2.03	0.00	0.00	0.09	2.13	0.28	6.36

--- Page 9 ---
3. Analytical Specificity/Interference: Interference studies for glucose, hemolysate, lipemia
(triglyceride-rich lipoproteins), conjugated bilirubin, unconjugated bilirubin, total protein,
and thrombocytosis were performed on the QScout system, using prepared low-normal and
high-normal WBC concentration samples collected from healthy donor whole blood in
K2EDTA or K3EDTA anticoagulated vacutainer tubes. Samples were tested in five to ten
(5â€“10) replicates on one of three analyzers using three (3) RLD test lots. The difference from
control was deemed acceptable if it was â‰¤ 10%.
The results of the interference studies demonstrated for WBC that:
â€¢ There was no significant glucose interference up to a concentration of 1000 mg/dL.
â€¢ There was no significant hemolysate interference up to a concentration of 1000
mg/dL.
â€¢ There was no significant lipemia interference up to a concentration of 1500 mg/dL.
â€¢ There was no significant conjugated bilirubin interference at a concentration of 40
mg/dL.
â€¢ There was no significant unconjugated bilirubin interference up to a concentration of
20 mg/dL.
â€¢ There was no significant total protein interference up to a concentration of 12.3 g/dL.
â€¢ There was no significant thrombocytosis interference up to a concentration of 750 x
103 platelets/Î¼L.
Nucleated Red Blood Cells (nRBCs): For nRBCs the QScout system raises a flag in the
presence of NRBCs â‰¥ 0.56 per 100 WBC. At levels lower than the threshold, there is no
interference with WBC differential parameters. For levels above the threshold, nRBC is
flagged and excluded from the WBC differential.
4. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
a) Sample Stability: Sample stability was determined with 11 freshly collected venous
normal and abnormal blood samples. The venous blood samples were collected into
K EDTA or K EDTA tubes and analyzed immediately (within one hour, baseline). The
2 3
samples were subsequently kept at room temperature (20â€“25Â°C) and were analyzed
again, with seven to nine (7â€“9) replicates at timepoints 2, 3, 4, 5, and 6 hours. The data
supports a sample stability claim of three (3) hours at room temperature.
b) QScout RLD Shelf-Life Stability: Six (6) lots of QScout RLD tests were stored out of
direct sunlight at 18-32Â°C in heat-sealed mylar packaging with testing at 2-week, 4-week,
and 2-, 3-, 6-, 9-, 12-, 15-, 18-, and 19-month timepoints. At each timepoint, four (4)
replicates each of a three-level biological control (low, normal, high) were run on one (1)
QScout Lab analyzer for each of the six QScout RLD test lots. The study is ongoing, and
the current data supports a shelf-life stability of 1 month.
c) Transport Stability: One (1) QScout RLD test lot underwent conditioning to simulate
transport in accordance with ASTM D7386 and temperature cycling. This involved
exposing QScout RLD tests to hazards occurring during transport, such as manual
handling, vibration, and altitude in accordance with ASTM D7386. RLD test lot then
K230878 - Page 9 of 14

--- Page 10 ---
underwent temperature cycling where the test lot was at room temperature then three (3)
days at 38Â°C followed by 24 hours at 18Â°C and finally at room temperature to simulate
the temperatures expected during shipment. The test kit maintained functionality and
expected analytical results during shipment.
d) QScout RLD In-Use Stability: The study was conducted to establish in-use stability of
the QScout RLD test when the QScout RLD test is removed from the storage box and
stored at the recommended storage conditions. Two (2) lots of RLD tests were tested.
Each test lot was stored at 18â€“32Â°C and tested at 0, 1, 2, 3, 4, 5, and 6 days, and then
evaluated using venous whole blood samples collected in K2EDTA or K3EDTA tubes.
The data supports the in-use stability for RLD tests for five (5) days.
e) QScout BCS Control Shelf-life stability: Three (3) levels (low, normal, high) were stored
at 2â€“8Â°C. Three (3) lots were evaluated with two (2) replicates per level per lot of BCS
control on one QScout Lab at defined timepoints. The study supports 105 days of shelf-
life stability for QScout BCS Control stored upright at 2â€“8Â°C.
f) QScout BCS Control In-Use stability: Four (4) replicates of each control level (3 levels-
low, normal, high) were measured on a single QScout Lab using a single lot of QScout
RLD at 0, 4, 7, 11, 14, and 15 days. The study supports 14 days of in-use stability for
QScout BCS Control.
g) Calibration Traceability: The QScout Lab WBC calibration process used the Beckman
Coulter Z2 particle counter as the reference instrument. The calibration process assigns a
reference value (R) to a fresh whole blood sample in the normal WBC range of 4.0 â€“ 12.0
x103/ÂµL. In parallel, the whole blood samples were run on four (4) QScout Lab analyzers
with 30 replicates and the mean WBC is calculated of which the value is being adjusted
by calibration (C). The mean calibration factor across the three fresh whole blood
samples is applied to the QScout Lab. The calibration traceability met the acceptance
criteria that all values must be within +/-5% of . Calibration
stability is ongoing and will be evaluated over 5 years. Testing will be conducted on Day
0, at months 1, ð‘ð‘2ð‘ð‘, ð‘ð‘að‘ð‘nð‘ð‘dð‘ð‘ 3ð‘ð‘ ð‘ð‘after Day 0, and then quarterly upð‘ð‘ tð‘ð‘oð‘ð‘ tð‘ð‘hð‘ð‘e ð‘ð‘fð‘ð‘irð‘ð‘sð‘ð‘t qð‘ð‘uð‘ð‘að‘ð‘rter of the sixth
year. The current data provided is for 1 month and supports stability < 1 month.
5. Detection Limit: The Limit of blank (LoB), Limit of detection (LoD), and limit of
quantitation (LoQ) for WBC was determined.
The LoB was determined using five (5) plasma samples assayed six times (6x) on two (2)
QScout Lab devices using two (2) QScout RLD lots for a total of 60 measurements for each
lot. The LoB for WBC was determined to be 0.02 x103/Î¼L.
LoD was determined using five (5) low level samples from K3EDTA venous whole blood.
Each of the prepared samples was assayed six times (6x) on each of the two (2) QScout Lab
devices using two (2) QScout RLD lots for a total of 60 measurements for each lot. The LoD
for WBC was determined to be 0.08 x103/Î¼L.
K230878 - Page 10 of 14

--- Page 11 ---
LoQ for was determined using four (4) low level samples from native venous whole blood.
Each of the prepared samples was assayed five times (5x) on each of the two (2) QScout Lab
devices using two (2) QScout RLD lots for a total of 40 measurements for each lot. The LoQ
for WBC was determined to be 0.38 x103/Î¼L.
6. Assay Cut-Off:
Not Applicable.
7. Accuracy (Instrument):
Refer to Method Comparison with Predicate Device below.
8. Carry-Over:
Not applicable.
B Comparison Studies:
1. Method Comparison with Predicate Device:
A method comparison study was performed at one (1) clinical laboratory site and seven (7)
point-of-care (POC) sites with 396 venous blood specimens collected in K EDTA or
2
K EDTA tubes. The study included normal and pathological samples to assess the QScout
3
Lab/RLD system performance across the analytical measurement ranges (AMRs) as well as
at medical decision points. Samples were obtained from patient >18 years of age with 12 of
the 396 samples contrived to cover the entire AMR. The pathological samples included the
following conditions: allergic reaction, anemia, autoimmune / rheumatological diseases, B12
or folate deficiency, bacterial infection, cardiovascular diseases, chronic inflammation,
hemoglobinopathies / hereditary RBC diseases, iron deficiency, acute and chronic leukemias
(lymphocytic or myelocytic), lymphoma, liver disease, myelodysplastic syndromes,
respiratory diseases, severe trauma or bleeding due to surgery or childbirth, solid tumor or
other oncological conditions, and viral infections. Each blood sample was analyzed in singlet
on the QScout Lab /RLD and in duplicate on the Beckman Coulter UniCel DxH 800 (manual
microscopy for IGs), but only the first replicate results was used for all data analyses. Bias
was determined based on the results of the Bland-Altman regression model. For the
regression analysis with 95% confidence intervals (CI) Deming (IG#) and Passing-Bablok
(all others) regression were used to determine by all sites combined. All results were within
the pre-defined acceptance criteria.
Regression Analysis â€“ All sites combined
Parameter Slope Intercept
N Sample range Pearson's r
103/Î¼L or % (95% CI) (95% CI)
1.008 0.020
WBC 396 0.51 - 59.45 0.996
(0.998, 1.020) (-0.033, 0.087)
0.976 0.078
NEUT# 396 0.00 - 45.87 0.985
(0.963, 0.987) (0.040, 0.125)
K230878 - Page 11 of 14

[Table 1 on page 11]
Parameter
103/Î¼L or %	N	Sample range	Slope
(95% CI)	Intercept
(95% CI)	Pearson's r
WBC	396	0.51 - 59.45	1.008
(0.998, 1.020)	0.020
(-0.033, 0.087)	0.996
NEUT#	396	0.00 - 45.87	0.976
(0.963, 0.987)	0.078
(0.040, 0.125)	0.985

[Table 2 on page 11]
Parameter
103/Î¼L or %

[Table 3 on page 11]
Slope
(95% CI)

[Table 4 on page 11]
Intercept
(95% CI)

--- Page 12 ---
Parameter Slope Intercept
N Sample range Pearson's r
103/Î¼L or % (95% CI) (95% CI)
1.036 -0.004
LYMPH# 396 0.08 - 41.15 0.972
(1.018, 1.053) (-0.027, 0.018)
1.100 -0.007
MONO# 396 0.00 - 13.06 0.907
(1.050, 1.146) (-0.030, 0.015)
0.900 0.010
EOS# 396 0.00 - 1.82 0.883
(0.867, 0.995) (0.004, 0.017)
0.720 0.010
BASO# 396 0.00 - 1.61 0.922
(0.644, 0.861) (0.010, 0.010)
1.194 -0.003
IG# 139 0.00 - 7.55 0.926
(1.004, 1.538) (-0.011, 0.003)
0.954 1.830
NEUT% 396 0.3 - 96.0 0.981
(0.939, 0.968) (0.882, 2.860)
0.983 0.719
LYMPH% 396 0.7 - 99.0 0.979
(0.968, 0.997) (0.430, 1.018)
0.985 0.603
MONO% 396 0.0 - 75.1 0.928
(0.931, 1.033) (0.264, 1.008)
0.897 0.129
EOS% 396 0.0 - 25.3 0.949
(0.860, 0.929) (0.092, 0.200)
0.889 -0.056
BASO% 396 0.0 - 4.9 0.690
(0.800, 1.000) (-0.100, 0.000)
0.862 0.471
IG% 139 0.0 - 21.5 0.896
(0.713, 1.010) (0.272, 0.671)
0.914 0.089
NLR 396 0.00 - 120.71 0.947
(0.891, 0.934) (0.060, 0.146)
2. Matrix Comparison:
The matrix comparison study was conducted to assess the comparison of K EDTA venous
3
whole blood and K EDTA venous whole blood on the QScout Lab. A total of 40 paired
2
patient venous whole blood samples were collected from each participant. The study was
conducted with one (1) replicate per sample at three (3) sites with trained operators.
Weighted Deming regression analysis was performed, and results were within the pre-
defined acceptance criteria, demonstrating the equivalency between K EDTA and K EDTA
2 3
whole blood.
D Clinical Studies:
1. Clinical Sensitivity:
The WBC flagging capability was evaluated for QScout by comparing to the WBC
differential results obtained by the microscopic 400-cell manual differential reference method
(2 slides/200 cells counted per slide) for 100 samples qualified as normal and 100 samples of
various abnormalities. The study was conducted by trained operators. Three blood film slides
K230878 - Page 12 of 14

[Table 1 on page 12]
Parameter
103/Î¼L or %	N	Sample range	Slope
(95% CI)	Intercept
(95% CI)	Pearson's r
LYMPH#	396	0.08 - 41.15	1.036
(1.018, 1.053)	-0.004
(-0.027, 0.018)	0.972
MONO#	396	0.00 - 13.06	1.100
(1.050, 1.146)	-0.007
(-0.030, 0.015)	0.907
EOS#	396	0.00 - 1.82	0.900
(0.867, 0.995)	0.010
(0.004, 0.017)	0.883
BASO#	396	0.00 - 1.61	0.720
(0.644, 0.861)	0.010
(0.010, 0.010)	0.922
IG#	139	0.00 - 7.55	1.194
(1.004, 1.538)	-0.003
(-0.011, 0.003)	0.926
NEUT%	396	0.3 - 96.0	0.954
(0.939, 0.968)	1.830
(0.882, 2.860)	0.981
LYMPH%	396	0.7 - 99.0	0.983
(0.968, 0.997)	0.719
(0.430, 1.018)	0.979
MONO%	396	0.0 - 75.1	0.985
(0.931, 1.033)	0.603
(0.264, 1.008)	0.928
EOS%	396	0.0 - 25.3	0.897
(0.860, 0.929)	0.129
(0.092, 0.200)	0.949
BASO%	396	0.0 - 4.9	0.889
(0.800, 1.000)	-0.056
(-0.100, 0.000)	0.690
IG%	139	0.0 - 21.5	0.862
(0.713, 1.010)	0.471
(0.272, 0.671)	0.896
NLR	396	0.00 - 120.71	0.914
(0.891, 0.934)	0.089
(0.060, 0.146)	0.947

[Table 2 on page 12]
Parameter
103/Î¼L or %

[Table 3 on page 12]
Slope
(95% CI)

[Table 4 on page 12]
Intercept
(95% CI)

--- Page 13 ---
were prepared for each sample for manual measurement. Two types of abnormalities were
evaluated: (1) distributional abnormal samples, which are samples where the quantity of at
least one of the parameters resides outside of the normal concentrations, and (2)
morphological abnormal samples, which includes atypical cell features, blasts, nucleated red
blood cells (NRBC), and atypical/variant lymphocytes contained in ordinary blood samples.
Overall agreement, sensitivity, and specificity were calculated with 95% confidence intervals
for distributional flagging, morphological flagging, and overall flagging performance.
Overall WBC Flagging, QScout versus Bloor Smear
Overall Agreement % Sensitivity % Specificity %
(95% CI) (95% CI) (95% CI)
Distributional Flagging 87.00 87.88 86.14
(81.53, 91.33) (79.78, 93.58) (77.84, 92.21)
Morphological Flagging 97.50 81.25 98.91
(94.26, 99.18) (54.35, 95.95) (96.13, 99.87)
Overall Flagging 87.00 88.00 86.00
(81.53, 91.33) (79.98, 93.64) (77.63, 92.13)
2. Clinical Specificity:
Refer to Clinical Sensitivity above.
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not Applicable.
E Clinical Cut-Off:
Not Applicable.
F Expected Values/Reference Range:
A reference interval study was conducted to establish adult reference intervals for all QScout
system parameters. The study was performed using venous whole blood samples collected from
265 (139 female and 126 male) apparently healthy adults (â‰¥ 18 years) at six (6) sites. Five (5)
QScout Labs, 24 RLD test lots, and eight (8) operators were used in the study. The lower and
upper limits of the 95% reference intervals were determined based on the 2.5th and 97.5th
percentiles of measurements for each sex group, respectively.
K230878 - Page 13 of 14

[Table 1 on page 13]
	Overall Agreement %
(95% CI)	Sensitivity %
(95% CI)	Specificity %
(95% CI)
Distributional Flagging	87.00
(81.53, 91.33)	87.88
(79.78, 93.58)	86.14
(77.84, 92.21)
Morphological Flagging	97.50
(94.26, 99.18)	81.25
(54.35, 95.95)	98.91
(96.13, 99.87)
Overall Flagging	87.00
(81.53, 91.33)	88.00
(79.98, 93.64)	86.00
(77.63, 92.13)

--- Page 14 ---
Parameter Female n=139 Male n=126
WBC x103 /ÂµL 4.00â€“11.30 3.78â€“12.12
NEUT# x103 /ÂµL 1.68â€“7.42 1.56â€“7.89
LYMPH# x103 /ÂµL 1.25â€“3.98 1.08â€“3.92
MONO# x103 /ÂµL 0.27â€“0.92 0.25â€“1.08
EOS# x103 /ÂµL 0.04â€“0.61 0.03â€“0.76
BASO# x103 /ÂµL 0.01â€“0.11 0.01â€“0.16
IG# x103 /ÂµL 0.00â€“0.04 0.00â€“0.06
NEUT% 33.8â€“71.4 33.7â€“75.0
LYMPH% 19.2â€“54.0 15.6â€“55.7
MONO% 4.8â€“13.2 4.6â€“13.1
EOS% 0.4â€“8.1 0.5â€“7.2
BASO% 0.2â€“1.5 0.1â€“2.2
IG% 0.0â€“0.5 0.0â€“0.7
NLR 0.63â€“3.76 0.62â€“4.89
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial
equivalence decision.
K230878 - Page 14 of 14

[Table 1 on page 14]
Parameter	Female n=139	Male n=126
WBC x103 /ÂµL	4.00â€“11.30	3.78â€“12.12
NEUT# x103 /ÂµL	1.68â€“7.42	1.56â€“7.89
LYMPH# x103 /ÂµL	1.25â€“3.98	1.08â€“3.92
MONO# x103 /ÂµL	0.27â€“0.92	0.25â€“1.08
EOS# x103 /ÂµL	0.04â€“0.61	0.03â€“0.76
BASO# x103 /ÂµL	0.01â€“0.11	0.01â€“0.16
IG# x103 /ÂµL	0.00â€“0.04	0.00â€“0.06
NEUT%	33.8â€“71.4	33.7â€“75.0
LYMPH%	19.2â€“54.0	15.6â€“55.7
MONO%	4.8â€“13.2	4.6â€“13.1
EOS%	0.4â€“8.1	0.5â€“7.2
BASO%	0.2â€“1.5	0.1â€“2.2
IG%	0.0â€“0.5	0.0â€“0.7
NLR	0.63â€“3.76	0.62â€“4.89